HOME >> MEDICINE >> NEWS
Study suggests statins can prevent sepsis in people with cardiovascular disease

Statins--the drugs used to lower cholesterol--may also reduce the risk of sepsis in patients with cardiovascular disease, according to a study published online today (Wednesday January 25, 2006) by The Lancet.

Sepsis is a serious medical condition that results from an overwhelming infection. People with cardiovascular disease have an increased risk of sepsis. When severe, sepsis can lead to multiple organ dysfunction including heart, lung, and kidney failure. Findings from animal studies suggest that statins might prevent sepsis but the effect in man has been unclear until now.

Donald Redelmeier (Sunnybrook & Women's Hospital, Ontario, Canada) andcolleagues' analysed data from over 69,000 people, aged over 65 years, with cardiovascular disease. The study group were all patients who had been hospitalised for acute coronary syndrome, stroke, or revascularisation; half had been prescribed statins after being discharged and half had not.

The data showed that after 2-years, 551 patients were admitted to hospital for sepsis in the statin group and 667 patients in the control group. This corresponds to a 19% reduction in the relative risk of sepsis for those taking statins. The authors call for randomised trials to test statins for the prevention of sepsis.

Dr Redelmeier states: "The use of statins in patients with atherosclerosis was associated with a significantly reduced risk of sepsis, including severe sepsis and fatal sepsis."

See also accompanying Comment.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
24-Jan-2006


Page: 1

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2016)... ... May 23, 2016 , ... ... and sexual objectification, according to Georgia State University researchers. , In ... in the fifth, sixth and seventh grades shared their experiences with strained ...
(Date:5/23/2016)... ... May 23, 2016 , ... Cosmetic Town, an ... about cosmetic procedures, began updating their library of over 300 encyclopedic medical articles. ... articles in order to feature the latest breakthroughs in plastic surgery procedures since ...
(Date:5/23/2016)... WASHINGTON, D.C. (PRWEB) , ... May 23, 2016 , ... ... Phyllis Greenberger, MSW, has decided to move on from that role. , “No one ... years as did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer ...
(Date:5/23/2016)... ... 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch and Rajat ... the end of 2016. , “We created IPOB to change the dialogue around ... back on what we have achieved, we’re gratified by the response of wine producers, ...
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a ... is proud to announce the launch of its new extended care program, Fifth Circle. ... treatment at Four Circles or another primary treatment program, Fifth Circle is designed to ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... SAN FRANCISCO, Calif. , May 19, 2016 /PRNewswire/ ... a biopharmaceutical company developing novel therapeutics for the treatment ... announced that new GBT440 data will be presented in ... 21 st Congress in Copenhagen ... ongoing Phase 1/2 GBT440-001 study in sickle cell disease ...
(Date:5/19/2016)... 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) ... treatment of multiple cancer and hematological indications, will be ... abstract titled " Clinical response in relapsed/refractory AML patients ... BL-8040, a potent CXCR4 antagonist; results of a Phase ... at the European Hematology Association 21st Congress, to be ...
(Date:5/19/2016)... CAMBRIDGE, Massachusetts , May 19, 2016 ... pharmaceuticals and diagnostics based on the gut microbiome, is pleased ... Cambridge, MA to support its operations ... office is located at Kendall Square, the heart of ... global hub for transforming scientific insights into new drugs. The ...
Breaking Medicine Technology:
Cached News: